Attovia Therapeutics, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Tao Fu
- Full Time Employees
- 44
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1091 Industrial Rd, Ste 310 San Carlos CA United States of America 94070
- IPO Date
- Aug 5, 2026
- CIK
- 0002058707
- Website
- attovia.com
- Similar Companies
- Business
- Atento S.A. (NYSE: ATTO) provides customer relationship management (CRM) and business process outsourcing (BPO) services, including sales, customer care, technical support, collections, back office, and business transformation outsourcing (BTO) augmented by artificial intelligence (AI), consulting, predictive analytics, and digital channels such as SMS, email, chats, social media, apps, and voice; it serves clients in telecommunications, financial services, consumer goods, retail, public administration, healthcare, travel, transportation, logistics, technology, and media sectors. The company operates primarily in Latin America, Brazil, the United States, Europe, the Middle East, and Africa, with approximately 127,000 employees. Founded in 1999 and headquartered in Luxembourg at 1 Rue Hildegard Von Bingen, Atento reinforces its strategic focus on Latin America and the United States through a November 2025 agreement to sell its Spanish operations to ABAI, enabling emphasis on AI-driven technologies, robotic process automation, and advanced analytics for customer experience transformation; it recently secured up to $30 million in additional liquidity in October 2025 and appointed Chris Condon as President and General Manager of its USNS region.
Company News
Attovia Therapeutics to Participate in Upcoming Investor Conferences
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More
Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source
Attovia Therapeutics (NASDAQ:ATTO) Director Acquires $1,785,000.00 in Stock
Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Global Strategic Fund Venbio Purchases 382,352 Shares of Stock
Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Redmile Group, Llc Purchases 200,000 Shares
Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq
Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering
Attovia Therapeutics Begins IPO Effort On Promising Early Trials
Atento call centers may have violated labor rights, Mexico says
Atento announces the successful implementation of its financial restructuring and unveils new business strategy leading the way to BTO (Business Transformation Outsourcing)
Atento appoints Álvaro Badiola Guerra as Group CFO
Atento announces drawdown of $17 million in tranche 2 funding under its new interim financing
Atento Announces Delisting from NYSE; Delisting expected in Restructuring Plan
NYSE to Commence Delisting Proceedings Against Atento S.A. (ATTO)
Penny Stocks To Buy? 3 AI Stocks To Watch Right Now
Fast-paced Momentum Stock Atento (ATTO) Is Still Trading at a Bargain
Here Is Why Bargain Hunters Would Love Fast-paced Mover Atento (ATTO)